80 research outputs found
Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate
<p>Abstract</p> <p>Background</p> <p>Cancer gene therapy by retroviral vectors is mainly limited by the level of transduction. Retroviral gene transfer requires target cell division. Cell synchronization, obtained by drugs inducing a reversible inhibition of DNA synthesis, could therefore be proposed to precondition target cells to retroviral gene transfer. We tested whether drug-mediated cell synchronization could enhance the transfer efficiency of a retroviral-mediated gene encoding herpes simplex virus thymidine kinase (HSV-<it>tk</it>) in two colon cancer cell lines, DHDK12 and HT29.</p> <p>Methods</p> <p>Synchronization was induced by methotrexate (MTX), aracytin (ara-C) or aphidicolin. Gene transfer efficiency was assessed by the level of HSV-TK expression. Transduced cells were driven by ganciclovir (GCV) towards apoptosis that was assessed using annexin V labeling by quantitative flow cytometry.</p> <p>Results</p> <p>DHDK12 and HT29 cells were synchronized in S phase with MTX but not ara-C or aphidicolin. In synchronized DHDK12 and HT29 cells, the HSV-TK transduction rates were 2 and 1.5-fold higher than those obtained in control cells, respectively. Furthermore, the rate of apoptosis was increased two-fold in MTX-treated DHDK12 cells after treatment with GCV.</p> <p>Conclusions</p> <p>Our findings indicate that MTX-mediated synchronization of target cells allowed a significant improvement of retroviral HSV-<it>tk </it>gene transfer, resulting in an increased cell apoptosis in response to GCV. Pharmacological control of cell cycle may thus be a useful strategy to optimize the efficiency of retroviral-mediated cancer gene therapy.</p
Rectal cancer with synchronous unresectable metastases: arguments for therapeutic choice
Environ 4 000 patients sont pris en charge chaque année en
France pour un cancer du rectum avec des métastases synchrones
jugées non résécables en réunion de concertation pluridisciplinaire
(RCP). Il nâexiste pas de consensus sur la stratĂ©gie
thérapeutique à proposer et parmi les trois options possibles, les
critÚres de choix restent relativement imprécis.
â La chirurgie premiĂšre est certes le meilleur traitement pour
contrĂŽler les symptĂŽmes rectaux mais elle nâa pas dĂ©montrĂ©
quâelle augmentait la survie et la rĂ©sĂ©cabilitĂ© secondaire des
métastases par rapport aux autres options et comporte un
risque de résection incomplÚte, de complications pouvant
retarder ou empĂȘcher la chimiothĂ©rapie, de progression accĂ©lĂ©rĂ©e
de la maladie métastatique et de mortalité comprise
entre 1 et 5 %.
â La radio-chimiothĂ©rapie premiĂšre suivie dâune chirurgie permet
le contrÎle des symptÎmes rectaux mais retarde la chimiothérapie
pour les métastases qui dominent le pronostic ; elle
expose aux mĂȘmes risques de complications que la chirurgie
premiĂšre.
â La chimiothĂ©rapie premiĂšre nous paraĂźt intĂ©ressante en
absence de complications locales sévÚres (occlusion, hémorragie)
; elle est potentiellement efficace sur les mĂ©tastases Ă
distance qui conditionnent le pronostic et sur la tumeur primitive
qui répond souvent de maniÚre similaire ; elle ne fige pas
la stratĂ©gie et offre la possibilitĂ© de lâadapter Ă chaque Ă©valuation
selon la réponse, la tolérance et les possibilités de résection
(tumeur primitive et métastases).
Dans tous les cas, il est fondamental de discuter ces dossiers au
cas par cas en RCP pour adapter la stratégie thérapeutique aux
caractĂ©ristiques du patient, de la tumeur primitive et de lâextension
mĂ©tastatique, ainsi quâĂ la rĂ©ponse obtenue aux traitements
proposés successivement.Rectal cancers with synchronous unresectable metastases are
diagnosed in about 4 000 patients. There is yet no consensus on
the therapeutic strategy for these cases which must be discussed
during multidisciplinary meeting. Three options are available
and arguments of choice remain relatively weak.
â First-line resection of the primary rectal tumour is indeed
the best treatment to control rectal symptoms but it does
not seem to improve survival and secondary resectability
of metastases when compared to other options; moreover
incomplete resection or complications may delay chemotherapy, accelerate the metastastic process and mortality
rate ranges from 1 to 5%.
â First-line radio-chemotherapy followed by surgery allows for
controlling rectal symptoms but delays chemotherapy for
metastases dominating the prognosis; it exposes the patients
to the same morbidity and mortality as first-line surgery.
â First-line chemotherapy is the third valid option in the absence
of major rectal symptoms (occlusion, haemorrhage); chemotherapy
is potentially efficient on distant metastases bearing a
high prognosis impact and on the primary rectal tumour, which
often has a similar response. First-line chemotherapy allows
for adapting the therapeutic strategy after each evaluation
according to the tumour response, side effects and possibility
of resection (primary rectal tumour and metastases).
In all cases, medical records of such patients should be discussed
during a multidisciplinary meeting to adapt the therapeutic
strategy to the patientâs characteristics, primary rectal tumor,
metastases staging and evolution
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks
<p>Abstract</p> <p>Background</p> <p>The identification of genomic signatures of colorectal cancer for risk stratification requires the study of large series of cancer patients with an extensive clinical follow-up. Multicentric clinical studies represent an ideal source of well documented archived material for this type of analyses.</p> <p>Methods</p> <p>To verify if this material is technically suitable to perform matrix-CGH, we performed a pilot study using macrodissected 29 formalin-fixed, paraffin-embedded tissue samples collected within the framework of the EORTC-GI/PETACC-2 trial for colorectal cancer. The scientific aim was to identify prognostic genomic signatures differentiating locally restricted (UICC stages II-III) from systemically advanced (UICC stage IV) colorectal tumours.</p> <p>Results</p> <p>The majority of archived tissue samples collected in the different centers was suitable to perform matrix-CGH. 5/7 advanced tumours displayed 13q-gain and 18q-loss. In locally restricted tumours, only 6/12 tumours showed a gain on 13q and 7/12 tumours showed a loss on 18q. Interphase-FISH and high-resolution array-mapping of the gain on 13q confirmed the validity of the array-data and narrowed the chromosomal interval containing potential oncogenes.</p> <p>Conclusion</p> <p>Archival, paraffin-embedded tissue samples collected in multicentric clinical trials are suitable for matrix-CGH analyses and allow the identification of prognostic signatures and aberrations harbouring potential new oncogenes.</p
Le foie bioartificiel interne
Le foie bioartificiel interne (FBAI), encore expĂ©rimental, peut reprĂ©senter une alternative intĂ©ressante Ă la transplantation hĂ©patique. Il a pour but de rĂ©aliser un foie auxiliaire transitoire, le temps dâobtenir la rĂ©gĂ©nĂ©ration du foie natif. Son principe repose sur la transplantation dâhĂ©patocytes isolĂ©s immunoprotĂ©gĂ©s par macroencapsulation, Ă lâintĂ©rieur de lâorganisme du receveur. Ces hĂ©patocytes peuvent ĂȘtre allogĂ©niques ou provenir dâanimaux, et, dans ce cas, ĂȘtre prĂ©parĂ©s Ă la demande, sans recourir Ă des mĂ©thodes de conservation. Le pĂ©ritoine est probablement le meilleur site dâaccueil du FBAI. Dans le futur, le FBAI pourrait ĂȘtre proposĂ© comme traitement de maladies mĂ©taboliques par dĂ©ficit enzymatique ou de certaines insuffisances hĂ©patiques aiguĂ«s ou chroniques avec encĂ©phalopathie. Il pourrait ĂȘtre Ă©galement un traitement transitoire en attente dâun greffon hĂ©patique
Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 andBM-40/SPARC genes
International audienc
- âŠ